Koyfin Home > Directory > Health Care > Arbutus Biopharma Cp > Capital Expenditures

Arbutus Biopharma Cp Capital Expenditures Chart (ABUS)

Arbutus Biopharma Cp annual/quarterly Capital Expenditures from 2010 to 2018.
  • Arbutus Biopharma Cp Capital Expenditures for the quarter ending December 12, 2018 was $1m a 127.22% increase of 1m year over year
  • Arbutus Biopharma Cp Capital Expenditures for the last 12 months ending September 09, 2018 was $-1m a -560.96% increase of 6m year over year
  • Arbutus Biopharma Cp Annual Capital Expenditures for 2017 was $-7m a 44.99% decrease of -3m from 2016
  • Arbutus Biopharma Cp Annual Capital Expenditures for 2016 was $-4m a 42.77% decrease of -2m from 2015
  • Arbutus Biopharma Cp Annual Capital Expenditures for 2015 was $-2m a 53.83% decrease of -1m from 2014
Other Cash Flow Metrics:
  • Arbutus Biopharma Cp Cash Flow from Operations for the quarter ending December 12, 2018 was $-17m a -16.70% increase of 3m year over year
  • Arbutus Biopharma Cp Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-36m a 63.34% decrease of -23m year over year
  • Arbutus Biopharma Cp Total Revenue for the quarter ending December 12, 2018 was $2m a 12.06% increase of 0m year over year
View Chart On Koyfin

Quarterly ABUS Capital Expenditures Data

12/2018$1m
09/2018$0m
06/2018$0m
03/2018$0m
12/2017$0m
09/2017$-1m
06/2017$-3m
03/2017$-3m
12/2016$-3m
09/2016$0m

Annual ABUS Capital Expenditures Data

2017$-7m
2016$-4m
2015$-2m
2014$-1m
2013$-1m
2012$0m
2011$0m
2010$-1m
2009$-2m